TY - JOUR
T1 - Long-term renal function after donor nephrectomy
T2 - Secondary follow-up analysis of the randomized trial of ketorolac vs placebo
AU - Grimsby, Gwen M.
AU - Andrews, Paul E.
AU - Castle, Erik P.
AU - Nunez, Rafael
AU - Mihalik, Laurie A.
AU - Chang, Yu Hui H.
AU - Humphreys, Mitchell R.
N1 - Funding Information:
Funding Support: This project was funded by a CR5 Mayo Clinic grant (08-000747) .
PY - 2014
Y1 - 2014
N2 - Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.
AB - Objective To evaluate the long-term safety of a novel continuous infusion of ketorolac vs placebo after laparoscopic donor nephrectomy. Methods We performed a secondary analysis of a previously reported randomized controlled trial conducted from October 7, 2008, to July 21, 2010. Patients aged 18-75 years received a continuous infusion of either ketorolac (treatment [n = 57]) or normal saline (control [n = 54]) for 24 hours immediately after laparoscopic donor nephrectomy. Serum creatinine levels were measured at 1- and 1.5-year follow-ups. Glomerular filtration rate was calculated preoperatively, postoperatively, and at 1- and 1.5-year follow-ups using the Chronic Kidney Disease Epidemiology Collaboration equation. Glomerular filtration rates were compared between treatment and control groups using 2-sample t tests. Results Data analysis for the 111 donor nephrectomy patients showed that glomerular filtration rates decreased in both groups over time, but changes were not clinically significant. No difference was found in glomerular filtration rates (in mL/min/1.73 m2) between treatment and control groups at 1-year follow-up (89.29 vs 87.94 mL/min/1.73 m2; P =.58) or at 1.5-year follow-up (88.54 vs 90.25 mL/min/1.73 m2; P =.51). Conclusion The novel provision of continuous steady-state ketorolac is safe for postoperative pain control in patients after donor nephrectomy, with no change in glomerular filtration rates between treatment and control groups acutely and at up to 1.5-year follow-up.
UR - http://www.scopus.com/inward/record.url?scp=84903639532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903639532&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2014.04.009
DO - 10.1016/j.urology.2014.04.009
M3 - Article
C2 - 24976224
AN - SCOPUS:84903639532
SN - 0090-4295
VL - 84
SP - 78
EP - 81
JO - Urology
JF - Urology
IS - 1
ER -